BAMS
LCTX icon

Bellevue Asset Management (Switzerland)’s Lineage Cell Therapeutics LCTX Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,842
Closed -$2K – 129
2015
Q3 		$2K Buy
+2,842
New +$7.36K ﹤0.01% 133

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s LCTX Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) sold out of Lineage Cell Therapeutics (LCTX) in Q4 2015, closing a stake of 2,842 shares — an estimated $2K sold.

Bellevue Asset Management (Switzerland) first reported a position in LCTX in Q3 2015 and held it in 1 quarter. The position peaked at $2K in Q3 2015. 68 funds tracked by Wall St. Rank hold LCTX as of Q4 2015.

  • Bellevue Asset Management (Switzerland) reported no remaining Lineage Cell Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Bellevue Asset Management (Switzerland) sold 2,842 Lineage Cell Therapeutics shares in Q4 2015, an estimated $2K.
  • Bellevue Asset Management (Switzerland) first reported a position in Lineage Cell Therapeutics in Q3 2015 and held it in 1 quarter.
  • Bellevue Asset Management (Switzerland)'s Lineage Cell Therapeutics position peaked at $2K in Q3 2015.
  • 68 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.